CorMedix Inc (CRMD):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7982)
◆英語タイトル:CorMedix Inc (CRMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7982
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:52
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
CorMedix Inc (CorMedix) is a commercial-stage pharmaceutical company that develops and commercializes therapeutic products for prevention and treatment of cardiac, renal and infectious diseases. The company offers neutrolin, a non-antibiotic anti-infective developed as a preventative solution to decrease the threat of infection and blood clots in central venous catheters (CVCs). It offers neutrolin product, which act as novel formulation of taurolidine, citrate and heparin provides preventative solution by decreasing the triple threat of infection. CorMedix also develops therapeutic products for the prevention and treatment of inflammatory diseases. The company markets its products through its distribution network located across the US. CorMedix is headquartered in Berkeley Heights, New Jersey, the US.

CorMedix Inc (CRMD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10
CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CorMedix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12
Licensing Agreements 13
CorMedix Enters into Licensing Agreement with NanoProteagen 13
Equity Offering 14
Cormedix to Raise USD15.61 Million in Public Offering of Shares 14
CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15
CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16
CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17
CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18
CorMedix Raises USD28.45 Million in Public Offering of Shares 20
CorMedix Completes Private Placement Of Units For US$7.4 Million 21
CorMedix Completes Private Placement Of Shares For US$1.5 Million 22
CorMedix Completes Private Placement Of Shares For US$1.5 Million 24
CorMedix Announces Private Placement Of Shares For US$2 Million 26
CorMedix Files Registration Statement For Public Offering Of Securities For US$30 Million 27
Debt Offering 28
CorMedix Completes Final Tranche Of Private Placement Of Notes For US$0.5 Million 28
CorMedix Inc – Key Competitors 29
CorMedix Inc – Key Employees 30
CorMedix Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 14, 2018: Cormedix reports second quarter financial results 32
May 15, 2018: Cormedix Announces First Quarter 2018 Financial Results 33
Mar 19, 2018: Cormedix Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update 34
Nov 09, 2017: CorMedix Reports Third Quarter Financial Results and Provides Business Update 36
Aug 09, 2017: CorMedix Reports Second Quarter Financial Results and Provides Business Update 38
May 10, 2017: CorMedix Reports First Quarter Financial Results and Provides Business Update 40
Mar 17, 2017: Cormedix Reports fourth quarter and full year 2016 financial results and provides business update 41
Corporate Communications 42
Aug 31, 2018: CorMedix announces NYSE american acceptance of plan to regain listing compliance 42
Aug 25, 2017: CorMedix Announces a Change to its Senior Leadership 43
Aug 07, 2017: CorMedix Appoints Gary Gelbfish, M.D., to Board of Directors 44
Jun 26, 2017: Cormedix Appoints Mehmood Khan, M.D. And Steven Lefkowitz to its Board of Directors 45
Jun 12, 2017: Cormedix Announces Changes to Board of Directors 47
Mar 02, 2017: Cormedix Appoints John L. Armstrong to Senior Leadership Team 48
Feb 01, 2017: Cormedix Announces New Appointments to Senior Leadership Team 49
Product News 50
09/07/2017: CorMedix Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially Deadly Fungal Pathogen Candida auris 50
Other Significant Developments 51
Feb 27, 2018: Cormedix provides update on its financing plans in connection with its ongoing lock-it 100 clinical study 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
CorMedix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CorMedix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CorMedix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10
CorMedix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CorMedix Enters into Co-Development Agreement with POETIC for CRMD-005 12
CorMedix Enters into Licensing Agreement with NanoProteagen 13
Cormedix to Raise USD15.61 Million in Public Offering of Shares 14
CorMedix Files Registration Statement for Public Offering of Shares for up to USD70 Million 15
CorMedix Plans to Raise up to USD20 Million in Public Offering of Shares 16
CorMedix to Raise USD5 Million in Private Placement of Preferred Shares 17
CorMedix Raises USD14 Million in Public Offering of Shares and Warrants 18
CorMedix Raises USD28.45 Million in Public Offering of Shares 20
CorMedix Completes Private Placement Of Units For US$7.4 Million 21
CorMedix Completes Private Placement Of Shares For US$1.5 Million 22
CorMedix Completes Private Placement Of Shares For US$1.5 Million 24
CorMedix Announces Private Placement Of Shares For US$2 Million 26
CorMedix Files Registration Statement For Public Offering Of Securities For US$30 Million 27
CorMedix Completes Final Tranche Of Private Placement Of Notes For US$0.5 Million 28
CorMedix Inc, Key Competitors 29
CorMedix Inc, Key Employees 30
CorMedix Inc, Subsidiaries 31

List of Figures
CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CorMedix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CorMedix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CorMedix Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ CorMedix Inc (CRMD):製薬・医療:M&Aディール及び事業提携情報(CorMedix Inc (CRMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆